NON SMALL CELL LUNG CANCER

This study tested a new combination treatment for people with advanced non-small cell lung cancer that has spread. Researchers combined two different types of radiation doses with immunotherapy drugs. The goal was to see if this approach could safely help control the cancer and d…

This study tested whether combining two existing cancer drugs, brentuximab vedotin and pembrolizumab, could help treat several types of advanced cancer that had spread to other parts of the body. It involved 161 people with metastatic melanoma, non-small cell lung cancer, or head…

This study tested the safety and effectiveness of combining two immunotherapy drugs, nivolumab and ALT-803, for adults with advanced non-small cell lung cancer that had worsened after prior treatment. The goal was to see if the combination could help control the cancer. The trial…

This early-stage study tested whether a personalized immune cell therapy called PB101 is safe when given alongside standard lung cancer drugs. Researchers collected immune cells from 8 patients with advanced EGFR-mutated lung cancer, grew them in a lab, and infused them back to h…

This early-stage trial tested adding an approved lung fibrosis drug, pirfenidone, to standard first-line chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe combined dose and get early signs of whether the combination could help sh…

This study tested whether adding immunotherapy drugs after standard chemoradiation could better control advanced lung cancer that cannot be surgically removed. Researchers compared two approaches: one drug alone versus two drugs combined, given to 105 patients whose cancer hadn't…

This study tested whether adding a new drug called gimistotug (BGB-A445) to other investigational treatments could help people with advanced non-small cell lung cancer whose previous treatments stopped working. The trial involved 35 participants who had already received standard …

This early-stage study aimed to find safe doses for several different combinations of cancer drugs in patients with advanced or metastatic solid tumors, including lung cancer. The 60 participants were divided into groups to test combinations of chemotherapy, immunotherapy, and ta…

This study tested whether combining two drugs, sotorasib and RMC-4630, could help control advanced non-small cell lung cancer with a specific genetic change called KRAS G12C. It involved 47 adults whose cancer had worsened despite trying standard treatments. The main goal was to …

This study tested a new treatment strategy for people with a specific type of advanced lung cancer. After initial chemo and radiation, patients with tiny amounts of leftover cancer in their blood were assigned to either continue their current immunotherapy drug (durvalumab) or sw…

This large, completed Phase 3 trial tested whether adding a new drug called tiragolumab to an existing immunotherapy (atezolizumab) works better than the immunotherapy alone for people with a specific type of advanced lung cancer who haven't had prior treatment. The study involve…

This study tested whether adding an experimental drug called TJ004309 to an existing immunotherapy (atezolizumab) could help control advanced cancers that have stopped responding to standard treatments. It involved 25 patients with specific types of advanced solid tumors, includi…

This study tested a new strategy for controlling advanced lung cancer that has spread. It aimed to see if using a sensitive blood test to detect tiny amounts of leftover cancer could guide doctors to use targeted radiation or surgery on the remaining tumors. The goal was to see i…

This small, early-stage study tested whether adding a new drug called copanlisib to an existing immunotherapy (durvalumab) could help patients with a specific type of advanced lung cancer. The main goal was to find a safe dose for the drug combination and see if it could help the…

This first-in-human study tested a new oral drug called JAB-3312 in 40 adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find the safest dose and see how the body processes the drug. Researchers also looked for early signs t…

This study tested a combination of two immunotherapy drugs, atezolizumab and bevacizumab, as a first treatment for adults with a specific type of advanced lung cancer. The main goal was to see how long patients could live without their cancer getting worse. The trial was complete…

This early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers that have specific KRAS mutations. The treatment was given after standard therapy to target any remaining cancer cells and prevent recurrence. Resear…

This study tested sotorasib as the first treatment for people with advanced non-small cell lung cancer who have a specific KRAS G12C mutation. The trial involved 42 participants who had not received prior treatment for their metastatic cancer. Researchers measured how well tumors…

This study tested a new drug, AZD3759, against standard treatments for people with advanced lung cancer that had spread to the brain. It involved 492 adults with a specific genetic mutation who had not yet received treatment. The main goal was to see if the new drug could keep th…

This study aimed to find out if patients and healthcare staff prefer a new under-the-skin injection for a lung cancer drug over the standard intravenous (IV) infusion. 179 adults with non-small cell lung cancer tried both methods. The main goal was to measure which way of getting…

This study tested whether adding a new drug called Imprime PGG to an existing immunotherapy (pembrolizumab) could help control advanced lung cancer that had worsened after initial chemotherapy. It involved 35 adults with metastatic non-small cell lung cancer. The research first a…

This study tested an experimental drug called AZD9291 for people in Asia Pacific with advanced non-small cell lung cancer. The participants had a specific genetic change (T790M mutation) and their cancer had gotten worse despite previous treatment with a common type of targeted t…

This large, completed Phase 3 trial tested whether adding a drug called lenvatinib to a standard immunotherapy (pembrolizumab) was better than the immunotherapy alone for people with advanced non-small cell lung cancer who had not yet received treatment. It involved 623 adults an…

This early-stage trial tested a new treatment for advanced lung cancer that has stopped responding to standard therapies. Doctors collected immune cells from 28 patients, genetically modified them in a lab to target cancer, and then infused them back into the patients. The main g…

This study tested whether adding an experimental drug called OSI-906 to the standard drug Tarceva could better control advanced non-small cell lung cancer in patients with specific genetic mutations. It involved 88 patients who had not yet received chemotherapy for their advanced…

This large, completed Phase 3 trial tested whether immunotherapy drugs (nivolumab with or without ipilimumab), alone or combined with chemotherapy, worked better than standard chemotherapy for people with advanced lung cancer who hadn't had prior treatment. It aimed to see if the…

This study tested the safety and effectiveness of a two-drug combination (encorafenib + binimetinib) for people with advanced non-small cell lung cancer that has a specific genetic change called a BRAF V600 mutation. It enrolled 98 adults whose cancer had spread and who had recei…

This early-stage study tested the safety and best dose of a new two-drug immunotherapy combination (BGB-A445 plus tislelizumab) in 204 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how much of the drugs patients cou…

This study followed 109 patients with advanced non-small cell lung cancer who had a specific genetic change (MET exon 14 skipping). After the drug Tabrecta was approved, researchers tracked everyone who took it for up to one year. The main goals were to monitor side effects, see …

This study tested whether adding a new drug called tiragolumab to an existing immunotherapy (atezolizumab) works better than the standard immunotherapy alone. It involved 135 people with advanced non-small cell lung cancer who had not yet received chemotherapy. The goal was to se…

This study tested if giving targeted radiation to several tumor sites before starting standard chemotherapy and immunotherapy could help people with advanced lung cancer live longer without their cancer getting worse. It involved 50 patients whose cancer had spread and who were e…

This study monitored the safety of Lorbrena, a lung cancer drug, in real-world patients after it was approved. It tracked 1,290 patients to understand what factors might lead to brain-related side effects or liver problems, especially when taking Lorbrena with certain other medic…

This study tested if a short, targeted dose of radiation given right before starting standard immunotherapy could improve results for people with advanced lung or head/neck cancer. The idea was that radiation might release cancer markers to help the immune drugs work better. Rese…

This study observed how well patients with advanced non-small cell lung cancer lived after receiving the drug nivolumab in real-world clinics in Greece and Cyprus. It followed 212 patients who had already tried chemotherapy, tracking their survival at 1, 2, and 3 years, their qua…

This study tested a new drug called BA3011, both alone and combined with an immunotherapy drug, for adults with advanced lung cancer that had worsened despite previous treatments. Researchers aimed to see if these approaches were safe and could shrink tumors or slow cancer growth…

This study tested a personalized approach to radiation therapy for people with inoperable stage III non-small cell lung cancer. Researchers used a mid-treatment PET scan to see how the tumor was responding. If the tumor was still active, they increased the radiation dose to that …

This study tested whether adding the immunotherapy drug serplulimab to standard chemotherapy, given both before and after surgery, could help people with operable non-small cell lung cancer. The goal was to see if this combination could shrink tumors more effectively before surge…

This study tested whether a new flexible surgical tool makes keyhole chest surgery for early-stage lung cancer easier and safer than the standard rigid tool. About 100 adults scheduled for this type of surgery were randomly assigned to have their operation with either the new fle…

This study tested a phone app and monitoring service designed to help minority patients with lung cancer better manage the side effects of their immunotherapy drugs. The goal was to help patients stay on their treatment longer and avoid unnecessary trips to the hospital. Research…

This early-stage study tested injecting a chemotherapy drug (cisplatin) directly into lung tumors before surgery. The goal was to see if this targeted approach is safe and might help the immune system fight cancer cells. Six people with early-stage, operable non-small cell lung c…

This early-stage study tested the safety of a new drug called GDC-1971 when given alongside standard cancer medications. It involved 10 patients with advanced lung or colorectal cancer whose disease had progressed despite previous treatments. The main goal was to find a safe dose…

This early-stage study tested a new oral drug called BAY2862789 in 45 people with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the body's own immune T-cells to fight cancer. Researchers primarily wanted to determine safe d…

This study tested if adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced non-small cell lung cancer that has spread. It involved 719 adults with newly diagnosed stage IV lung c…

This study tested a combination of three drugs—nivolumab, ipilimumab, and paclitaxel—for people newly diagnosed with advanced non-small cell lung cancer that had spread. The main goal was to see if this combination could safely control the cancer and delay its progression. It inv…

This study tested a new combination of two drugs, NT-I7 and pembrolizumab, for people with advanced solid tumors that had returned or stopped responding to prior therapies. The main goals were to find a safe dose and see if the combination could shrink tumors in several hard-to-t…

This study tested an experimental drug called DS-1062a for people with advanced non-small cell lung cancer that had specific genetic changes. The 137 participants had already tried targeted therapies and chemotherapy that stopped working for them. Researchers measured how well th…

This early-stage study aimed to find a safe and effective dose of a new drug called TPST-1495, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors. It enrolled 89 adults with cancers like colorectal, lung, and head and neck cancer …

This study tested an experimental drug called AK112 in 108 people with advanced non-small cell lung cancer. AK112 is a single antibody designed to attack cancer in two ways at once: by blocking a protein that helps tumors hide from the immune system and by cutting off their blood…

This was a first-in-human study to test the safety and early effectiveness of a new drug called CHS-388 for people with advanced solid tumors. The trial enrolled 145 adults with cancers like kidney, liver, and lung cancer that had progressed after standard treatments. Researchers…

This study tested whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy before lung cancer surgery is better than chemotherapy alone. It involved 505 people with early-stage, operable non-small cell lung cancer. The goal was to see if …

This study tested whether giving a drug called tislelizumab, either alone or combined with other drugs, before surgery could help shrink tumors in people with early-stage lung cancer. It involved 121 Chinese adults whose cancer could be removed by surgery. The main goal was to se…

This study tested a drug called trastuzumab deruxtecan for people with advanced non-small cell lung cancer that has a specific genetic change called a HER2 mutation. The 152 participants had already tried at least one prior treatment that included platinum chemotherapy. The main …

This study tested a new, more convenient way to give an existing lung cancer drug. Researchers compared giving the medicine as an under-the-skin injection to the standard method of an IV drip. The goal was to see if the injection worked just as well and was safe for people with a…

This study tested a new blood test method designed to detect genetic changes in advanced non-small cell lung cancer. Researchers analyzed blood samples from 22 patients to see if the test could reliably identify these changes compared to standard tissue-based tests. The goal was …

This study tested whether combining a blood test (liquid biopsy) with traditional tissue analysis could better identify specific genetic changes in patients with advanced non-small cell lung cancer. Researchers enrolled 581 newly diagnosed patients to compare how well each method…

This study tested a new scanning method to see if it could make PET scans better at finding small lung tumors. It involved 103 adults who had small lung nodules. Researchers compared images from a standard PET scan to images from a new scan that was timed with the patient's breat…

This study tested new blood tests designed to detect cancer biomarkers in patients with recurrent or metastatic head & neck, lung, or skin cancer. The goal was to validate if these 'liquid biopsies' could accurately track cancer changes over time by analyzing genetic material in …

This study tested whether involving family members in a structured palliative care program could improve the well-being of patients with advanced lung cancer. Over 8 weeks, 110 patients received either standard care or this special family-supported program. Researchers measured q…

This study tested the safety of a shorter radiation schedule called 'Quad Shot' for people with advanced lung cancer who were also receiving standard drug treatments. The goal was to see if this faster approach could help control symptoms like cough or shortness of breath while c…

This study tested whether a nutritional drink rich in specific building blocks of protein (essential amino acids) could help the body build muscle in people with advanced lung cancer who were losing weight. Researchers compared this special drink to a standard protein mix in 41 p…

This study tested a home-based exercise program designed to help people manage severe fatigue after lung cancer surgery. Researchers worked with 235 patients who had non-small cell lung cancer to see if starting exercises right after surgery or waiting 6 weeks worked better. The …

This study aimed to better understand non-small cell lung cancer by analyzing specific protein fragments in tumor tissue. Researchers collected and examined tissue samples from 56 patients with lung cancer to see how these proteins are expressed and whether they relate to disease…

This study aimed to find biological markers in the blood and tumors of lung cancer patients that could predict who would benefit from the immunotherapy drug atezolizumab. It involved 100 patients with advanced non-small cell lung cancer whose disease had progressed after prior tr…

This study aimed to understand why some lung cancers become resistant to targeted drugs. Researchers used a simple blood test, instead of a tissue biopsy, to look for genetic changes in 62 patients with ALK-positive lung cancer whose cancer had started growing again during treatm…

This early-stage study aimed to understand how a new lung cancer drug candidate, calderasib, interacts with two common medications (midazolam and digoxin) in the body. Researchers gave healthy volunteers the new drug along with the other medicines to see if it changed how their b…

This study aimed to understand if a patient's emotional state before treatment, along with certain blood markers, could predict how well they respond to immunotherapy. Researchers observed 196 adults with advanced lung or gastroesophageal cancer who were starting their first trea…

This study tested whether a more detailed type of PET scan could better predict if lung cancer returns within one year after treatment. Researchers compared this advanced scan method to standard PET scans in 40 patients with non-small cell lung cancer who received chemo-radiation…

This study tested a new lab analysis using six markers from a patient's tumor sample. The goal was to see if this test could predict, before treatment starts, which patients with advanced non-small cell lung cancer would respond well to a combination of immunotherapy (pembrolizum…

This study aimed to see if analyzing real-world electronic health records from cancer clinics could produce results similar to a major, controlled clinical trial. Researchers looked at data from over 4,800 patients with a specific type of advanced lung cancer to compare the effec…

This study created a regional database to track 518 non-small cell lung cancer patients who had specific genetic mutations detected through a central testing lab in Lille. Researchers collected detailed medical information to understand how different mutations affect patients' tr…

This study looked at whether simple blood tests could help doctors monitor when lung cancer becomes resistant to certain medications. Researchers analyzed medical records and blood samples from 70 advanced lung cancer patients in Tunisia who were taking targeted drugs. They wante…

This study looked back at the medical records of 350 Australian patients with advanced lung cancer who had a specific genetic change (EGFR mutation). Researchers analyzed how long patients stayed on a targeted drug called osimertinib, and how it affected their survival, when it w…

This study tested how a new lung cancer drug (AZD9291) affects the body's processing of a common cholesterol medication (simvastatin). Researchers enrolled 52 patients with advanced lung cancer that had stopped responding to standard treatments. The goal was to understand potenti…

This study aimed to see if early PET scans could predict how well a standard immunotherapy drug (pembrolizumab) would work for advanced lung cancer. Researchers followed 40 patients with advanced lung cancer who were already scheduled to receive this treatment. They performed PET…